内容加载…
编辑器加载…
类加载…
当在学术写作中引用证据时，你应该总是尽量引用主要(原始)来源。这通常是第一次陈述信息的期刊文章。在大多数情况下，Physiopedia的文章是次要来源，因此不应用作参考文献。Physiopedia的文章最好用于查找原始信息来源(参见文章底部的参考文献列表)。
如果您认为这篇Physiopedia文章是您所引用的信息的主要来源，您可以使用下面的按钮访问相关的引用声明。
引用的文章
您没有编辑此页的权限，原因如下:
您请求的操作仅限于组中的用户:定义/描述==[[图片:Cells.jpg|450x350px|右|无边框]]]急性淋巴细胞白血病(Acute lymphoblastic leukemia, ALL)是一种[[血液]]和骨髓的癌症。骨髓是充满长骨腔的海绵状组织，由脂肪、红细胞和白细胞组成。ALL影响未成熟的白细胞。*急性白血病占所有儿童恶性肿瘤的30%。ALL是儿童中最常见的癌症。反复感染、出血或治疗无效的疲劳/苍白应引起ALL的怀疑。这种癌症分为两种亚型之一。梅奥诊所。急性淋巴细胞白血病。2010。可在:http://www.mayoclinic.com/health/acute-lymphocytic-leukemia/DS00558/TAB=indepth。2011年3月7日发布。American Cancer Society. Leukemia—Acute Lymphocytic Overview. 2010. Available at: http://www.cancer.org/Cancer/Leukemia-AcuteLymphocyticALLinAdults/OverviewGuide/leukemia-all-overview-what-causes. Accessed March 7, 2011.National Marrow Donor Program. Acute Lymphblastic Leukemia. 2011. Available at: http://www.marrow.org/PATIENT/Undrstnd_Disease_Treat/Lrn_about_Disease/ALL/index.html. Accessed March 7, 2011.The Chicago University Medical Center. Adult Acute Lymphoblastic Leukemia Treatment. 2011. Available at: http://www.uchospitals.edu/online-library/content=CDR257989 . Accessed March 7, 2011. # '''B-cell'''- produce antibodies to fight infections. #*Common ALL (50% of cases) #*Early Pre-B ALL (10% of cases) #*Pre-B ALL (10% of cases) #*Mature B-cell ALL (4% of cases) #'''T-cell'''- assist B-cells in producing antibodies to fight infections. #*Pre-T ALL (5-10% of cases) #*Mature T-cell (15-20% of cases) '''Prognostic factors include''':University of Maryland Medical Center. Acute Lymphocytic Leukemia- Prognosis. 2011. Available at: http://www.umm.edu/patiented/articles/how_characteristics_of_acute_lymphocytic_leukemia_cells_prognosis_000086_7.htm . Accessed March 7, 2011. *Age: Younger patients have a better prognosis compared to older patients. The cure rate of children is approximately 80% and only 40% for adults. *Initial white blood cell (WBC) count: Patients diagnosed with a WBC count below 50,000 tend to do better than patients with higher WBC counts. *ALL subtype: The subtype of T cell or B cell affects prognosis. Patients with T-cell ALL tend to have a better prognosis than those with mature B-cell ALL. *Response to chemotherapy: Patients who achieve complete remission within 4 to 5 weeks of starting treatment tend to have a better prognosis. Patients who do not achieve remission at any time have a poor prognosis. Evidence of minimal presence of leukemia cells in the bone marrow may also positively affect prognosis. 回到 检索自"http:///Acute_Lymphoblastic_Leukemia”
回到 检索自"http:///Acute_Lymphoblastic_Leukemia”
